Literature DB >> 16724896

Use of Surgicel for sealing nephrostomy tract after totally tubeless percutaneous nephrolithotomy.

S M K Aghamir1, M H Khazaeli, A Meisami.   

Abstract

BACKGROUND AND
PURPOSE: Fibrin glue and gelatin matrix have been used to seal nephrostomy tracts to reduce bleeding and extravasation after tubeless percutaneous nephrolithotomy (PCNL). In this study, Surgicel (oxidized cellulose) was used to seal the nephrostomy tract after totally tubeless PNL. PATIENTS AND METHODS: Twenty patients with kidney calculi were treated with totally tubeless PNL. According to randomization, at the conclusion of surgery, the nephrostomy tracts were sealed with Surgicel in ten patients and left unsealed in the other ten. Postoperatively, the two groups were compared with respect to hematocrit changes and extravasation as detected by abdominal ultrasonography and wound-dressing inspection.
RESULTS: There was statistically significant decrease in the hematocrit in both the study (P = 0.017) and the control (P = 0.003) group. When the two groups were compared with respect to the decrease in hematocrit, no statistically significant difference was seen (P = 0.241). Similarly, extravasation from the nephrostomy tract was not significantly different in the two groups.
CONCLUSION: Sealing the nephrostomy tract with Surgicel after totally tubeless PNL did not decrease bleeding or extravasation from the tract.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16724896     DOI: 10.1089/end.2006.20.293

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  17 in total

1.  Current Status of Hemostatic Agents and Sealants in Urologic Surgical Practice.

Authors:  Sashi S Kommu; Robert McArthur; Amr M Emara; Utsav D Reddy; Christopher J Anderson; Neil J Barber; Raj A Persad; Christopher G Eden
Journal:  Rev Urol       Date:  2015

2.  Totally tubeless percutaneous nephrolithotomy: a prospective randomized controlled study.

Authors:  Chien-Hsing Chang; Chung-Jing Wang; Shi-Wei Huang
Journal:  Urol Res       Date:  2011-02-18

3.  Keyhole surgery of the kidney at sultan qaboos university hospital, oman.

Authors:  Mohammed S Al-Marhoon; Josephkunju Mathew; Hawraa Al-Lawati
Journal:  Sultan Qaboos Univ Med J       Date:  2007-08

Review 4.  The management of the access tract after percutaneous nephrolithotomy.

Authors:  Tanja Hüsch; Michael Reiter; René Mager; Eva Steiner; Thomas R W Herrmann; Axel Haferkamp; David Schilling
Journal:  World J Urol       Date:  2015-04-23       Impact factor: 4.226

5.  Comparison of outcomes in totally tubeless percutaneous nephrolithotomy according to nephrostomy tract sealing with fibrin versus gelatin matrix: a propensity score matching study.

Authors:  Jung Jun Kim; Yoon Seok Suh; Deok Hyun Han
Journal:  Urolithiasis       Date:  2019-03-14       Impact factor: 3.436

Review 6.  Hemostatic agents used for nephrostomy tract closure after tubeless PCNL: a systematic review and meta-analysis.

Authors:  Cui Yu; Zhou Xu; Wang Long; Liu Longfei; Zeng Feng; Qi Lin; Zu Xiongbing; Chen Hequn
Journal:  Urolithiasis       Date:  2014-07-27       Impact factor: 3.436

7.  The use of adjunctive hemostatic agents in tubeless percutaneous nephrolithotomy: a meta-analysis.

Authors:  Jiawu Wang; Chengyao Zhang; Guangzhong Tan; Bo Yang; Wenkai Chen; Dan Tan
Journal:  Urolithiasis       Date:  2014-09-09       Impact factor: 3.436

8.  Tubeless percutaneous nephrolithotomy.

Authors:  Madhu Sudan Agrawal; Mayank Agrawal
Journal:  Indian J Urol       Date:  2010 Jan-Mar

9.  New instrumentation in percutaneous nephrolithotomy.

Authors:  Joseph W Pugh; Benjamin K Canales
Journal:  Indian J Urol       Date:  2010-07

10.  Tubeless percutaneous neprolithotomy: the new gold standard.

Authors:  Tawfik H Al-Ba'adani; Khaled M Al-Kohlany; Abdulelah Al-Adimi; Mansour Al-Towaity; Taher Al-Baadani; Mohammed Alwan; Mohammed Al-Hussieni; Shehab Al-Germozi; Mokhtar Al-Masani; Khalid Al-Badwy; Ibrahiem H El-Nono
Journal:  Int Urol Nephrol       Date:  2007-12-19       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.